[en] OBJECTIVE: This study aims to evaluate a topical treatment based on silymarin/methylsulfonilmethane (S-MSM) to improve erythematous-telangiectactic rosacea. METHODS: Forty-six patients affected by stage I-III rosacea entered this double-blind, placebo-controlled study. Subjects were treated for 1 month. Clinical and instrumental evaluations were done at baseline, after 10 and 20 days, and at the end of the study. Itching, stinging, erythema, and papules were investigated clinically as well as hydration and erythema instrumentally with capacitance and color measurements. RESULTS: A statistically significant improvement was observed in many clinical and instrumental parameters investigated (P < 0.001). In particular, improvement of skin redness, papules, itching, hydration, and skin color occurred. CONCLUSIONS: The combination of silymarin and S-MSM can be useful in managing symptoms and condition of rosacea skin, especially in the rosacea subtype 1 erythemato-telangiectatic phase. The action can be considered multicentric and multiphase because of the direct modulating action on cytokines and angiokines normally involved and up-regulated in the case of such skin condition.
Disciplines :
Dermatology
Author, co-author :
Berardesca, Enzo
Cameli, Norma
Cavallotti, Claudia
Levy, Jean Luc
Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie
de Paoli Ambrosi, Gianfranco
Language :
English
Title :
Combined effects of silymarin and methylsulfonylmethane in the management of rosacea: clinical and instrumental evaluation.
Oztas MO, Balk M, Ogus E, Bozkurt M, Ogus IH, Ozer N. The role of free oxygen radicals in the aetiopathogenesis of rosacea. Clin Exp Dermatol 2003; 28: 188-92.
Murphy G. Ultraviolet light and rosacea. Cutis 2004; 74 (3 Suppl.): 13-6, 32-4.
Bonamigo RR, Bakos L, Edelweiss M, Cartell A. Could matrix metalloproteinase-9 be a link between Demodex folliculorum and rosacea? J Eur Acad Dermatol Venereol 2005; 19: 646-7.
Rigopoulos D, Kalogeromitros D, Gregoriou S et al. Randomized placebo-controlled trial of a flavonoid-rich plant extract-based cream in the treatment of rosacea. J Eur Acad Dermatol Venereol 2005; 19: 564-8.
Berardesca E, Borroni G. Instrumental evaluation of cutaneous hydration. Clin Dermatol 1995; 13: 323-7.
Pierard GE. EEMCO guidance for the assessment of skin colour. J Eur Acad Dermatol Venereol 1998; 10: 1-11.
Schmutz JL. Rosacea and UV light. Ann Dermatol Venereol 2006; 133: 467-9.
Jones D. Reactive oxygen species and rosacea. Cutis 2004; 74 (3 Suppl.): 17-20, 32-4.
Yale SH, Vasudeva S, Mazza JJ et al. Disorders of flushing. Compr Ther 2005; 31: 59-71.
Jiang C, Agarwal R, Lu J. Anti-angiogenic potential of a cancer chemopreventive flavonoid antioxidant, silymarin: Inhibition of key attributes of vascular endothelial cells and angiogenic cytokine secretion by cancer epithelial cells. Biochem Biophys Res Comm 2000; 276: 371-8.
Singh RP, Dhanalakshmi S, Agarwal C, Agarwal R. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: Implications for angioprevention and antiangiogenic therapy. Oncogene 2005; 24: 1188-202.
Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis. Cancer Epidemiol Biomarkers Prev 2003; 12: 933-9.
Usha PR, Naidu MU. Randomised, double-blind, parallel, placebo-controlled study of oral glucosamine, methylsulfonylmethane and their combination in osteoarthritis. Clin Drug Invest 2004; 24: 353-63.
Magnuson BA, Appleton J, Ryan B, Matulka RA. Oral developmental toxicity study of methylsulfonylmethane in rats. Food Chem Toxicol 2007; 45: 977-84.
